Literature DB >> 17127386

Protein i: interference at protein level by intrabodies.

Jayapal Manikandan1, Peter N Pushparaj, Alirio J Melendez.   

Abstract

Immunoglobulin molecules have long been used in biomedical research as in vitro tools for identification, purification and functional manipulation of target proteins. The specificity and diversity of immunoglobulins can be exploited to target a wide range of intracellular proteins by expressing them in vivo. Such antibody molecules, which are expressed intracellularly and directed to defined sub-cellular compartments, are termed 'intrabodies'. They represent a new and versatile tool that has the potential to manipulate diverse biological processes. Gene knockout, antisense and small interfering RNA knockdown techniques, are employed to characterize the function of many gene products and to validate these gene products as potential drug targets for novel therapeutics, but they have their limitations. The experimental results to date suggest that intrabodies represent a powerful alternative to modulate protein function and analyze its effects. Moreover, they can also be utilized to target specific domains of a particular target protein. Even though their clinical application might take a long time, they can play an important role for target identification and validation in functional genomics and/or proteomics. Here we review the latest advances in the concept, construction and applications of Intrabodies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17127386     DOI: 10.2741/2152

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  7 in total

Review 1.  Therapeutic antibodies: successes, limitations and hopes for the future.

Authors:  Patrick Chames; Marc Van Regenmortel; Etienne Weiss; Daniel Baty
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

Review 2.  Targeting Pyk2 for therapeutic intervention.

Authors:  Christopher A Lipinski; Joseph C Loftus
Journal:  Expert Opin Ther Targets       Date:  2010-01       Impact factor: 6.902

3.  The Pyk2 FERM domain as a target to inhibit glioma migration.

Authors:  Joseph C Loftus; Zhongbo Yang; Nhan L Tran; Jean Kloss; Carole Viso; Michael E Berens; Christopher A Lipinski
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

4.  Deciphering the key molecular and cellular events in neutrophil transmigration during acute inflammation.

Authors:  Srinivasan Dinesh Kumar; Kandamaran Krishnamurthy; Jayapal Manikandan; Praveen N Pakeerappa; Peter Natesan Pushparaj
Journal:  Bioinformation       Date:  2011-04-22

5.  Gephyrin selective intrabodies as a new strategy for studying inhibitory receptor clustering.

Authors:  Paola Zacchi; Elena Dreosti; Michela Visintin; Matteo Moretto-Zita; Ivan Marchionni; Isabella Cannistraci; Zeynep Kasap; Heinrich Betz; Antonino Cattaneo; Enrico Cherubini
Journal:  J Mol Neurosci       Date:  2007-11-16       Impact factor: 3.444

6.  Gene silencing by cell-penetrating, sequence-selective and nucleic-acid hydrolyzing antibodies.

Authors:  Woo-Ram Lee; Ji-Young Jang; Jeong-Sun Kim; Myung-Hee Kwon; Yong-Sung Kim
Journal:  Nucleic Acids Res       Date:  2009-12-09       Impact factor: 16.971

7.  RNAi and RNAa--the yin and yang of RNAome.

Authors:  Peter Natesan Pushparaj; Joseph Jude Aarthi; Srinivasan Dinesh Kumar; Jayapal Manikandan
Journal:  Bioinformation       Date:  2008-01-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.